The Inflation Reduction Act was designed to lower drug prices.
It is lowering drug prices.
A separate process is underway at the same time. The Bureau files its assessment of the second process.
The Two Clocks
The IRA's Medicare Drug Price Negotiation Program operates on a schedule. A small-molecule drug — the kind that comes in pill form, is manufactured at relatively low cost, and is prescribed to most people who take prescription drugs — becomes eligible for negotiation selection 7 years after FDA approval. Prices take effect at year 9.
A biologic — the kind administered by injection or infusion, manufactured through living cell cultures, requiring refrigerated storage, specialty pharmacy dispensing, and in many cases an infusion center visit — becomes eligible for negotiation selection 11 years after approval. Prices take effect at year 13.
The difference between these two clocks is 4 years.
BUREAU NOTE: The 7-year and 11-year figures appear in the statute, in the CMS program documentation, in the KFF policy analysis, and in the legal commentary published within weeks of the law's passage. The differential was a design choice. The Bureau is not disclosing it; the Bureau is noting what happened next.
The Inventory of Optimization
The pharmaceutical industry received the two-clock structure in August 2022, when the IRA was signed into law. The Bureau presents the following inventory of what has been filed since.
The Pfizer Pivot
Pfizer's oncology portfolio in 2023 was 94% small molecules. Pfizer has disclosed that by 2030, 65% of its oncology revenue will come from biologics. The company acquired Seagen — a leading developer of antibody-drug conjugates, which are biologics — for $43 billion in 2023.
A Pfizer executive, Suneet Varma, stated the reason directly: "Biologics have that 13-year versus the 9-year [for small molecules] before you enter negotiation or price negotiations, so I think that all of that strengthens the case."
The case for the slower clock.
The Clinical Trial Divergence
In the 29 months following IRA passage, industry-sponsored clinical trial starts for small-molecule drugs fell 25.2% for pre-approval trials and 29.5% for post-approval trials. Biologic trial starts showed no statistically significant decline.
This finding, published in the Journal of Medical Economics in March 2026, rules out the obvious alternative explanation. A general market contraction would have affected both categories. The divergence is specific to small molecules. The divergence is consistent with the clock.
The Funding Reallocation
Aggregate small-molecule investments by biopharmaceutical companies valued under $2 billion — the early-stage companies where new drug categories are born — fell 68% since the IRA was introduced. That figure comes from a peer-reviewed study published in Therapeutic Innovation & Regulatory Science in April 2025.
In the first seven months of 2024, biologics received ten times more funding than small molecules. Seventy-eight percent of pharmaceutical companies surveyed by the Information Technology and Innovation Foundation expect to cancel early-stage small-molecule pipeline projects. Over 75% of venture capital firms surveyed are planning to divest from small-molecule companies.
Before the IRA, between 2010 and 2014, 64 of 113 biotech IPOs focused on small-molecule production versus 17 on biologics.
The ratio is now reversing.
BUREAU NOTE: A question the Bureau has entered into its records: if a law produces a measurable investment response within 29 months of passage — a response documented in peer-reviewed journals, disclosed in corporate investor presentations, and confirmed in bipartisan Congressional legislation — at what point does the word "unintended" stop applying? The Bureau notes that University of Chicago economists published projections of this outcome in October 2023, citing 188 fewer small-molecule treatments. Their projections preceded the Vital Transformation study, the Pfizer disclosure, and the clinical trial divergence data. The Bureau files this timeline without characterization.
The Drugs Being Negotiated
The Bureau now presents the composition of the negotiated drug list.
The IRA's first 10 Medicare-negotiated prices took effect January 1, 2026. Seven of the 10 drugs are small molecules: Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Imbruvica. Three are biologics.
In January 2025, CMS announced the next 15 drugs selected for negotiation — the drugs whose prices will take effect in 2027. All 15 are small molecules.
Twenty-two of the first 25 drugs selected for Medicare price negotiation are small molecules. The program is negotiating prices on the drug category for which clinical trial investment has fallen 25-29%, funding has fallen 68%, and Pfizer has begun a multi-billion-dollar strategic exit.
The negotiation is working.
The pipeline the negotiation is addressing is being vacated.
The Bipartisan Acknowledgment
On April 15, 2025, President Trump signed Executive Order 14273 directing the Department of Health and Human Services to work with Congress to equalize the negotiation timelines for small molecules and biologics.
The bipartisan EPIC Act (H.R. 1492), introduced in 2025, proposes setting small-molecule negotiation eligibility at 11 years — the same as biologics.
Neither the executive order nor the proposed legislation eliminates the negotiation program. Both acknowledge that the 4-year differential is a structural distortion in pharmaceutical development.
The Bureau notes that this acknowledgment is bipartisan, legislative, and executive. It is not an accusation. It is a finding that has already been filed in Congress, in the White House, and in peer-reviewed literature.
BUREAU NOTE: A final inventory item, from University of Chicago economists Philipson et al. (2023): under the IRA's current timelines, the projected outcome is 188 fewer small-molecule treatments — 79 new drugs that will not be developed, and 109 post-approval indications that will not be pursued. The study's authors call this a conservative estimate. The Bureau records the number and does not adjudicate the projection. The Bureau notes that the number has a name: it is the count of the drugs the pipeline contains that the pipeline will not produce. Whether the negotiation savings balance the count is a question the Bureau is not competent to answer. The Bureau files only what can be documented. What can be documented is this: the clock was set, the industry moved to the slower one, the movement is in the data, and the data are not in dispute.
The Bureau of Pharmaceutical Incentive Compliance is a sub-department of the Bureau of Public Agreement™. It files assessments of incentive structures that have produced documented outcomes. It does not offer remediation. Remediation is the work of the EPIC Act, Executive Order 14273, and the 119th Congress. The Bureau wishes them well with their calendar.